Intra-Cellular Therapies ( NASDAQ:ITCI ) witnessed a sharp increase in its stock value, as it surged by 25% on Tuesday, following the success of its drug Caplyta in a depression treatment study. The drug has already been approved for the treatment of schizophrenia and depressive episodes in bipolar disorder patients, and the recent study has indicated its...
WATCHING $ITCI for ENTRY TARGET @ 37.23 Practicing to nail my entries even tighter… if target hits I will take a position. Just because I'm watching doesn't mean I will actually take a position. I guess it just depends on what my portfolio is doing at the moment. Intra-Cellular Therapies... That just sounds intense... I put this one on my watch list for next week.
$ITCI Reverse H&S - Holding $25 Support Expecting a bounce off $25 near term. Targeting $30 gap-fill from January. Bullish options activity recently - $5M bullish bet on $30 strike Aug calls yesterday Note: Not investment advice.
Looks like we gonna get some nice uptrend in the next few days.
ITCI up 20% on the week and further 30% upside ahead! Looking to test 2019 resistance area around 14.50 ahead of its scheduled PDUFA approval on Dec.27th. TP 2 16.50.
ITCI was in our watch list for a while, and now it seems ready to go. Good insider buying from10% owner. We think it has Right now it is testing MA 200 resistance & it if can break above it can go much higher. On the option side we would consider August $12.50 calls @ $1.50 and November $15.00 calls @ $1.20 * Trade Criteria * Date First Found- July 20,...